Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
Date:5/6/2008

ting of the

American Association for Cancer Research. Data from this Phase 1

trial of oral picoplatin showed that picoplatin can achieve oral

bioavailability and supports further clinical development. These

results enable further clinical trials of oral picoplatin in new

combinations with radiation and oral chemotherapies as well as

targeted agents.

* Platinum Resistance: In April, we also announced preclinical

findings demonstrating that picoplatin retains its activity in SCLC

cell lines made resistant by treatment with cisplatin, carboplatin

or oxaliplatin. The data suggests that picoplatin may overcome

platinum resistance induced by currently available platinum agents.

We also announced an agreement with AltheaDx to use its Express

Pathway platform to identify molecular signatures that may be

correlated with platinum resistance. The identification of molecular

signatures of platinum resistance may lead to the development of

biomarkers for platinum resistance.

* Picoplatin Drug Substance Manufacturing: We announced an agreement

with W. C. Heraeus GmbH for the manufacture and supply of picoplatin

drug substance to support our clinical trials and commercial product

needs.

Management Appointments

* Appointed Robert De Jager, M.D., as chief medical officer of the

Company who brings a depth of experience to our clinical development

programs to help the company position picoplatin for the global

oncology marketplace

First Quarter 2008 Unaudited Financial Results

The Company reported a net loss of $9.9 million ($0.29 diluted loss per share on a loss applicable to common shares of $10.0 million) for the first quarter of 2008 compared to a net loss of $7.7 million ($0.34
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
5. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
6. Onyx Pharmaceuticals Reports 2008 First Quarter Results
7. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
8. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
9. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
(Date:1/15/2014)... Biotechnology Company, Limited ("TaiGen") today announced that they have ... pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ® ... Turkey and other members of ... for the treatment of bacterial infections including those caused ...
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... , SEATTLE, Aug. 3 Anyone touched by ... play fair. But in order to expose exactly how cancer cells ... orderly cooperation of normal cells. , , ... - which enhances the potential for learning how cancer cells cheat ...
... Aug. 3 Human Genome Sciences, Inc. (Nasdaq: ... of 26,697,250 newly issued shares of its common stock at ... includes 3,482,250 shares sold upon exercise by the underwriters of ... to the Company from the offering are approximately $356.7 million, ...
... , , , ... Senomyx, Inc. (Nasdaq: SNMX ), a leading company focused ... for the food, beverage, and ingredient supply industries, and Firmenich SA, ... they have entered into a collaborative research, development, commercialization and license ...
Cached Biology Technology:W.M. Keck Foundation Awards $1 Million to Hutchinson Center Scholar to Study How Cells Go Awry 2Human Genome Sciences Announces Closing of Public Offering 2Human Genome Sciences Announces Closing of Public Offering 3SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 2SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 3SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 4SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 5
(Date:4/17/2014)... Double-stapled peptide inhibits RSV infection , Respiratory ... lower respiratory tract infections, generating life-threating illness in ... preventive therapies are limited. RSV enters host cells ... a six-helix fusogenic bundle. Small interfering peptides that ... however, these peptides are highly susceptible to degradation. ...
(Date:4/17/2014)... 16, 2014. Kessler Foundation has been named awardee ... the Department of Defense Spinal Cord Injury Research ... for the randomized, double-blinded, controlled, multi-site clinical trial, ... muscle strength after spinal cord injury. Dr. Forrest ... Research at Kessler Foundation. Two additional sites will ...
(Date:4/17/2014)... developed at Sandia National Laboratories and recently licensed to ... cheaper. , Bacillus anthracis , the bacteria ... over the world and can cause serious, and often ... can survive in harsh conditions for decades. In humans, ... skin contact, inhalation of spores or eating contaminated meat. ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... , , , , ... AUDIO: James Perfield discusses how the oil is similar to many vegetable oils ... , , , , , ... , , , , , , , COLUMBIA, Mo. Scientists have ...
... who decide to go wreck another community, prostate and ... a new University of Michigan study. Now, U-M ... target and eventually overrun the bone marrow niche, a ... and white blood cells, said Russell Taichman, professor at ...
... Project ended a decade ago, scientists thought that they,d closed ... genes. But what they really did was open a Pandora,s ... Aviv University,s Cohn Institute for the History and Philosophy of ... studies concerned with epigenetics, Prof. Jablonka concludes that some of ...
Cached Biology News:Plant oil may hold key to reducing obesity-related medical issues, MU researcher finds 2Plant oil may hold key to reducing obesity-related medical issues, MU researcher finds 3Prostate cancer spreads to bones by overtaking the home of blood stem cells 2Prostate cancer spreads to bones by overtaking the home of blood stem cells 3Traumatizing your DNA 2
... highly sensitive laser confocal systems designed for ... scanners that meet your expectations, differentiating between ... optimizing the signal on the bottom as ... range for increased sensitivity. Results with VersArray ...
... Simultaneously perform 96 assays on one ... one microarray plate with 96 (7mm x ... protein, gene expression, or screening analysis studies. ... compression fit gasket, eliminating the presence of ...
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
... vapor-tight adhesive chambers for sealing hybridization reactions on ... a sample on a glass slide. Reaction solution ... the ports are then sealed with plastic sealing ... allow exchange of reaction fluid. These chambers enclose ...
Biology Products: